IPP Bureau
Bayer and Samsung take action against sleep disturbances associated with menopause
By IPP Bureau - June 06, 2024
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
Melissa Seymour to join Lilly as executive vice president of Global Quality
By IPP Bureau - June 06, 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
Melissa Seymour to join Lilly as executive vice president of Global Quality
By IPP Bureau - June 06, 2024
Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry
AstraZeneca completes acquisition of Fusion Pharmaceuticals
By IPP Bureau - June 05, 2024
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma
By IPP Bureau - June 05, 2024
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
AstraZeneca’s Tagrisso plus chemo recommended for approval in EU
By IPP Bureau - June 05, 2024
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Moderna & Merck announce 3-year data for mRNA-4157 in combination with Keytruda
By IPP Bureau - June 05, 2024
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Aurigene Pharmaceutical opens biologics facility in Genome Valley, Hyderabad
By IPP Bureau - June 04, 2024
The state-of-the-art facility is equipped with best-in-class equipment and control systems
Merck's oncology pipeline of DDRi and ADC poised to advance cancer treatment
By IPP Bureau - June 04, 2024
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL
By IPP Bureau - June 04, 2024
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
PharmaLytica 2024: India exported US$ 27.8 billion worth of drugs in FY 2023-24
By IPP Bureau - June 03, 2024
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Supriya Lifescience FY24 PAT up 32%
By IPP Bureau - June 03, 2024
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
NTPC, Tata Memorial Centre launch cancer awareness initiative
By IPP Bureau - June 03, 2024
The cancer screening and awareness camp will run for four months in the Mira Bhayander Region, benefiting approximately 5,000 police personnel
Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma
By IPP Bureau - June 03, 2024
The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas
